Amarantus Bioscence - WKN: A1J9ZB - MEGA NEWS $$$$

Seite 48 von 67
neuester Beitrag: 25.04.21 03:33
eröffnet am: 27.12.12 09:39 von: Antont Anzahl Beiträge: 1673
neuester Beitrag: 25.04.21 03:33 von: Inesbcaga Leser gesamt: 171738
davon Heute: 219
bewertet mit 3 Sternen

Seite: Zurück 1 | ... | 45 | 46 | 47 |
| 49 | 50 | 51 | ... | 67  Weiter  

01.03.13 17:50

3795 Postings, 5483 Tage schultebrandtrendwende in sicht ?

Real-Time Best Bid & Ask
0.0775 / 0.0779 (1 x 1)Why is size 1?  

01.03.13 17:51

654 Postings, 5241 Tage Goldesel2010jep...

Es geht mal wieder in die richtige Richtung...  

01.03.13 17:52

3795 Postings, 5483 Tage schultebrandwurde auch zeit.....

01.03.13 18:18

19504 Postings, 4561 Tage berliner-nobodysollte nun wirklich starten

 
Angehängte Grafik:
sc.png (verkleinert auf 72%) vergrößern
sc.png

01.03.13 18:24

3795 Postings, 5483 Tage schultebrandschön wäre ein sk über 0,10$.......

aber da wollen wir mal nicht zu viel verlangen.  

01.03.13 18:26

3186 Postings, 4207 Tage Obelaxsollten heut nicht news kommen?

01.03.13 18:26

15800 Postings, 4404 Tage nordküstenbaubin dabei

sieht saustark aus  

01.03.13 18:31
1

292 Postings, 7868 Tage Zocker24so

bin auch dabei. Uns allen viel Glück  

01.03.13 18:38

3795 Postings, 5483 Tage schultebrandna dann kanns ja losgehen....

aber die herztropfen nicht vergessen......geht schon mal recht turbulent zu, bei amarantus..  

01.03.13 18:42

15800 Postings, 4404 Tage nordküstenbauAmarantus Bio

0,0799 USD
01.03.13  18:41  

01.03.13 18:43

19504 Postings, 4561 Tage berliner-nobodyder chart welcher aus sieht wie handgemacht

und sich wohl wieder holen wird nur noch höher :)

 
Angehängte Grafik:
p.gif
p.gif

01.03.13 18:44

15800 Postings, 4404 Tage nordküstenbauAmarantus Bio

im Chartverlauf erkennt man genau das bisherige Hoch bei 0,18 USD  

01.03.13 18:46

19504 Postings, 4561 Tage berliner-nobodysollten die nächsten phasen erreicht

werden der diagnostic programm oder manf zu kllinischen studien zu gelassen, kannst du das hoch vergessen  

01.03.13 19:16

15800 Postings, 4404 Tage nordküstenbauAmarantus Bio

alles ist möglich bei den Amigos, 0,1 USD heute?  

01.03.13 19:22

19504 Postings, 4561 Tage berliner-nobody10 cent heute

wäre der knaller.

ich denke so oder so das sie diagnostic sparte bei marktreife verkaufen werden  

01.03.13 19:23

3795 Postings, 5483 Tage schultebrand#1189 du meinst 50% aufschlag.......?

bin zwar optimistisch......wäre aber schon toll wenn sich dieses niveau halten würde.  

01.03.13 19:24

19504 Postings, 4561 Tage berliner-nobodyintern geschätzer marktwert

800 usdollar alles nach zulesen auf der homepage

bei 225 mio aktien, das hat potenzial

und dann werden sie sich nur auf manf konzentrieren

geschätzer markt wert auch intern 5 milliarden usdollar  

02.03.13 09:00

868 Postings, 6093 Tage mariosapfberlin

hallo,

sind die aktien in berlin noch handelbar? gestern gab es ja keine umsätze !?

danke für die info !  

02.03.13 09:45

881 Postings, 4883 Tage sauerland1502Kurse werden gestellt, Handel ist aber bis auf

weiteres eingestellt! Musste drüben kaufen!  

04.03.13 16:01

3795 Postings, 5483 Tage schultebrandläuft weiter.......

aktuell

Real-Time Best Bid & Ask
0.084 / 0.085 (1 x 1)Why is size 1?  

04.03.13 16:37

1047 Postings, 4372 Tage File083So.

bin auch mal drin..mal schauen was hier so geht.. Weiß einer was zum Termin am 06.03?

 

05.03.13 23:57

19504 Postings, 4561 Tage berliner-nobodyhier kann viel gehen

Short Term Indicators Average: 40% Buy Medium Term Indicators Average: 25% Sell Long Term Indicators Average: 67% Buy Overall Average: 16% Buy MACD kreutzt bulish

 

http://www.barchart.com/quotes/stocks/AMBS

Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Conference
Related Stocks

AMBS - Amarantus Biosci Inc

Amarantus       BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering       and developing treatments and diagnostics for diseases associated with       the neurodegeneration and apoptosis centered around its patented       therapeutic protein MANF, Brewer       Sports International (BSI) and Toi Cook Management Group (TCMG)       today announced joint hosting of the Coalition for Concussion Treatment       (#C4CT) Concussion Awareness Conference (#C4CT Conference) in       Minneapolis on June 19, 2013 at the Minneapolis Club.

The #C4CT Conference is the opening event of the three-day Brewer Sports       Symposium, which also includes the 3rd Annual Sports Law for       Rookies and Veterans CLE and Sports and Social Impact seminar. The #C4CT       Conference will focus on important scientific, medical, translational       and prevention-related topics of Traumatic Brain Injuries (TBI) and       their long-term impacts on athletes and soldiers. Conference panels will       include industry experts, international business leaders and current and       former professional athletes. The Brewer Sports Symposium is part of the 8th       Annual Blue Carpet Celebrity Weekend hosted by The Jack Brewer       Foundation.

"Traumatic Brain Injuries and their effects on amateur and professional       football players are emerging as a rallying point to better understand       the brain and how we can improve currently available methods to treat       it," said Gerald E. Commissiong, President and CEO of AMBS. "We are       proud to be among the first to unite the groups directly affected by       these issues, in particular current and former professional athletes,       with the scientists, physicians and entrepreneurs who will ultimately       lead the way in developing solutions to these devastating problems. We       believe that by educating athletes on the basics of concussions, and       what additional resources are needed to achieve certain critical steps       on the road to better treating the brain, we will give all parties a       chance to partake in this emerging field of medical research."

The #C4CT Conference will include presentations and panel discussions on       the following key topics:

--        Scientific understanding of Traumatic Brain Injury and the long-term         scientific implications

--        Current medical practice and what doctors believe are the key areas of         unmet medical need

--        Translational models available and additional tools needed to         accelerate research

--        Innovative approaches currently being considered

Jack Brewer, CEO of BSI, explains, "When advising athletes, we       frequently get the question of how to deal with concussions as well as       the desire to better understand the issue at hand and how to help. As an       ex-NFL player, I personally have experienced hundreds of violent       collisions throughout my career and have several teammates and friends       who suffer the lasting effects of Traumatic Brain Injury. This is a       passion of mine and BSI is committed to helping advance TBI research and       development. By providing educational opportunities such as the #C4CT       Conference, it is our goal to enable those directly impacted to make       informed decisions as well as provide tangible investment opportunities       surrounding the advancement of research and treatment methods for       concussions."

Toi Cook, Amarantus Advisor, former Super Bowl champion with the 1994       San Francisco 49ers and 11 year starting NFL defensive back said, "As a       player representative for the entirety of my NFL career, my focus was       the welfare and safety of the players. Although the current situation in       professional sports regarding concussions is alarming and has raised       serious issues, I am encouraged by the fact that we are all now much       more aware of the problem and need for solutions. Now is the time to       act, and through our work with partners like Amarantus and BSI and with       conferences such as #C4CT, we can make a difference and impact lives       while maintaining the integrity of sport."

 
Angehängte Grafik:
sc.png (verkleinert auf 72%) vergrößern
sc.png

06.03.13 12:27

19504 Postings, 4561 Tage berliner-nobodyinteressant

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

2013-03-06 05:00 ET - News Release

 

NOKOMIS, Fla. -- (Business Wire)

Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new medical technologies and innovations, today reports its anticipation of partnering with a cutting-edge genome-mapping facility in Houston in the next few weeks.

The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017. The cutting-edge science of pharmacogenomics is a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.

RBCC sees it as the future of medicine.

“This is the next evolution in personalized medicine,” said RBCC CEO Patrick Brown. “Important differences in drug metabolism and response from person to person are often rooted in our genes. By studying a patient’s genotype, doctors can eliminate the trial-and-error approach to tailoring a safer, more efficient and more effective drug treatment plan.”

RBCC is turning its full attention to the exploration of new promising opportunities now that the company will no longer be partnering with Amarantus Biosciences, which has elected to pursue other opportunites. RBCC wishes Amarantus much success moving forward, and remains open to future partnering opportunities with the company.

In addition to its pharmacogenomics talks, RBCC is also currently working on a joint venture agreement with a privately held drug delivery company that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before.

For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).

http://www.stockwatch.com/News/...6&symbol=RBCC&news_region=U

 

Seite: Zurück 1 | ... | 45 | 46 | 47 |
| 49 | 50 | 51 | ... | 67  Weiter  
   Antwort einfügen - nach oben